Background Limited efficacy of IV recombinant tissue plasminogen activator (rt-PA) for large vessel occlusions (LVO) raises doubts about its utility prior to endovascular therapy. Purpose To compare outcomes and hospital costs for anterior circulation LVOs (middle cerebral artery, internal carotid artery terminus (ICA-T)) treated with either primary endovascular therapy alone (EV-Only) or bridging therapy (IV+EV)). Methods A single-center retrospective analysis was performed. Clinical and demographic data were collected prospectively and relevant cost data were obtained for each patient in the study. Results 90 consecutive patients were divided into EV-Only (n=52) and IV+EV (n=38) groups. There was no difference in demographics, stroke severity, or clot distribution. The mean (SD) time to presentation was 5:19 (4:30) hours in the EV-Only group and 1:46 (0:52) hours in the IV+EV group (p
Digital Commons Citation
Rai, Ansaar T.; Boo, SoHyun; Buseman, Chelsea; Adcock, Amelia K.; Tarabishy, Abdul R.; Miller, Maurice M.; Roberts, Thomas D.; Domico, Jennifer R.; and Carpenter, Jeffrey S., "Intravenous thrombolysis before endovascular therapy for large vessel strokes can lead to significantly higher hospital costs without improving outcomes" (2018). Clinical and Translational Science Institute. 728.
Rai AT, Boo S, Buseman C, et al. Intravenous thrombolysis before endovascular therapy for large vessel strokes can lead to significantly higher hospital costs without improving outcomes. Journal of NeuroInterventional Surgery. 2017;10(1):17-21. doi:10.1136/neurintsurg-2016-012830